Skip to content

OÜ PharmaMint

Registry code (registrikood) 14960867Private limited company (Osaühing)VAT EE102252015Activity (EMTAK 47731): Ravimite jaemüükActive

Tallinn, Harju County · Financial data: annual reports up to 2025; tax data up to 2026 Q3

Revenue (2025)
€6.3M
▲ 49.3% vs 2024
Profit before tax (2025)
-€576k
Employees, FTE (2025)
19
State taxes paid, last 4 quarters
€781k

Revenue, profit and employees, 2020–2025

€148k2020€1.1M2021€2.3M2022€2.7M2023€4.2M2024€6.3M2025
YearRevenue (müügitulu)Operating profit (ärikasum)Net profitEquity (omakapital)Employees, FTE
2020€147,699-€89,249-€89,248-€86,7484
2021€1,115,315-€690,601-€711,841-€798,5897
2022€2,298,326-€957,891-€1,012,629-€1,811,2187
2023€2,657,259-€1,263,860-€1,423,950-€3,235,16814
2024€4,209,578-€956,146-€1,214,548-€4,449,71616
2025€6,285,855-€296,798-€575,659-€5,025,37519

Balance sheet summary

YearCashTotal assetsCurrent liabilitiesNon-current liabilitiesEquity
2020€28,472€145,365€232,113—-€86,748
2021€122,642€800,833€549,422€1,050,000-€798,589
2022€116,785€754,291€865,509€1,700,000-€1,811,218
2023€142,167€593,983€879,151€2,950,000-€3,235,168
2024€121,979€781,952€1,121,668€4,110,000-€4,449,716
2025€118,155€1,073,203€6,098,578—-€5,025,375

Calculated ratios

Net profit margin = net profit ÷ revenue. Equity ratio = equity ÷ total assets. Seedata sources & methodology for how each figure is derived.

Quarterly tax and turnover data (EMTA)

QuarterState taxes paidWage taxesTurnoverEmployees
2022 Q1€23,239€16,576€632,8138
2022 Q2€30,757€16,779€826,3169
2022 Q3€56,041€18,798€704,1239
2022 Q4€48,448€12,471€1,005,29012
2023 Q1€20,500€16,618€722,96313
2023 Q2€72,287€31,640€883,59214
2023 Q3€83,547€48,782€976,05514
2023 Q4€80,388€52,431€1,278,28915
2024 Q1€74,794€49,797€1,089,82314
2024 Q2€122,424€53,929€998,49014
2024 Q3€82,107€54,273€1,172,93714
2024 Q4€146,663€53,096€1,827,15816
2025 Q1€113,366€76,891€1,793,60217
2025 Q2€183,105€63,179€1,917,78417
2025 Q3€142,862€70,176€1,418,47218
2025 Q4€240,321€69,576€2,327,34218
2026 Q1€193,798€97,955€2,021,75419
2026 Q2€185,053€68,491€2,478,60520
2026 Q3€161,622€74,343€2,004,33218

Source: EMTA quarterly published data, as of 10 October 2026. Covers state taxes and wage taxes actually paid and turnover and employee counts as declared by the company, not the annual report figures above.

About this data

In the 2025 financial year (period 1 January 2025–31 December 2025), OÜ PharmaMint reported revenue of €6,285,855.

The company recorded a net loss of €575,659 in the 2025 financial year.

Revenue increased by 49.3% from €4,209,578 in 2024 to €6,285,855 in 2025.

Revenue grew at a compound annual rate of 111.7% between 2020 and 2025.

Equity accounted for -468.3% of total assets of €1,073,203 at the end of the 2025 reporting period.

With 19 full-time-equivalent employees in 2025, revenue per employee was €330,834.

Across the 4 most recent quarters declared to EMTA, up to Q3 2026, OÜ PharmaMint reported €8,832,033 in turnover.

EMTA recorded 18 employees for the quarter ending Q3 2026, compared with 19 full-time-equivalent employees in the 2025 annual report.

Browse

Source

Source: Estonian e-Business Register open data (Centre of Registers and Information Systems, RIK), licence CC BY-SA 4.0, modified; Estonian Tax and Customs Board (EMTA) quarterly data. Downloaded 2026-11-16. This is not an official register extract — see ariregister.rik.ee.

Company data on this site is available under CC BY-SA 4.0.

To request a correction or the removal of this page, use the contact form. Removal requests are handled within 30 days, no justification required.